Latham Counsels Juno Therapeutics in US$1 Billion Strategic Collaboration with Celgene Corporation

Team led from Silicon Valley guides the alignment of two major biopharma companies for the development and commercialization of immunotherapies to treat cancer and autoimmune diseases.

June 29, 2015

Celgene Corporation (Nasdaq:CELG) and Juno Therapeutics, Inc. (Nasdaq:JUNO) has announced a global collaboration for the development and commercialization of immunotherapies. The two companies will leverage T cell therapeutic strategies to develop treatments for patients with cancer and autoimmune diseases with an initial focus on Chimeric Antigen Receptor Technology (CAR-T) and T Cell Receptor (TCR) technologies. Upon closing, Juno will receive an upfront payment of approximately $150 million, and in addition Celgene will purchase 9,137,672 shares of Juno’s common stock at $93.00 per share.

Latham & Watkins LLP represents Juno Therapeutics in the agreement with a corporate team led from the firm’s Silicon Valley office by partners Judith Hasko and Robert Koenig. Associates Kate Hillier, Marshall Olin, Vincent Chuang and Gil Ofir provided transactional support, and counsel Geoff Kuziemko and associates Lia Smith and Sophie Yu assisted in intellectual property matters. Advice is also being provided on antitrust matters by partner Joshua Holian and counsel Sydney Smith; and on tax matters by partners Kirt Switzer and Grace Chen, with assistance by associate Una Au.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.